Anti-CYLD

0.5 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide. CYLD is involved in multiple physiological processes including immune response, osteoclastogenesis and spermatogenesis. It is a tumor suppressor via its negative regulation of NF-kB activation. CYLD is a deubiquitinase, removing ubiquitin chains from tumor-necrosis factor receptor-associated factor 2 (TRAF2) and thereby preventing its activation of IkB, a regulator of NF-kB. NF-kB remains sequestered in the cytoplasm, unable to translocate to the nucleus and initiate cell survival and oncogenetic signaling. Protein function: Protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation (PubMed:12917689, PubMed:12917691). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis. Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane, this process does not depend on NF-kappa-B activation. [The UniProt Consortium]